Investment case
Zymeworks Inc.
ZYME · 2 developments mapped · last assessed 2026-09-10
Market Ontology has mapped 2 macro, policy, and market developments to Zymeworks Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ZYME yet, so no modelled value is shown. The ZYME valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ZYME on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger
Direct impact on merger completion probability and potential legal costs.
· Moves probability of merger completion, synergy realization timeline, legal expenses
- Open question
Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR
Direct acquisition of a public company, impacting financial structure, pipeline, and operational integration.
· Moves future growth rates (pipeline expansion), synergy realization (cost savings, r&d efficiency), cost of capital (financing structure for acquisition)
What changed, by assumption
- 2026-09-10Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger
- 2026-08-21Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-06-29 | Cost of capital | Bullish | Higher cost-of-debt tranche lifts blended WACC. | 0.70 |
| 2026-06-29 | Interest expense | Bullish | High-yield coupon materially raises interest burden. | 0.70 |
| 2026-06-29 | Net debt | Bullish | Sub-IG debt raise increases leverage and net debt. | 0.70 |
| 2026-06-29 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-06-29 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-06-29 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-10 | Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger | Bearish | 1-3m | 0.70 |
| 2026-08-21 | Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR | mixed | 3-12m | 0.70 |